Novel method lowers IOP after Ahmed glaucoma valve implantation neovascular glaucoma

In patients with neovascular glaucoma, Ahmed Glaucoma Valve implantation and cyclophotocoagulation performed at the same time significantly lowered intraocular pressure at 3 and 6 months compared to Ahmed glaucoma valve implantation alone, according to a study.

In this retrospective pilot study, 55 eyes of 54 patients who had neovascular glaucoma and underwent Ahmed glaucoma valve implantation only, Ahmed glaucoma valve implantation with cyclophotocoagulation, or cyclophotocoagulation only had intraocular pressure recorded at 1-, 3-, and 6-month intraocular pressure.

At 3 and 6 months, there was significantly lower intraocular pressure in the combined treatment group compared to the Ahmed glaucoma valve-only group (P = 0.03 and P <0.001, respectively).

There was no significant difference in hypertensive phase occurrence between the combined treatment group and the valve-alone group.

There was significantly lower IOP in the cyclophotocoagulation-only group compared to the Ahmed glaucoma valve-only group at 3 months (P = 0.006).

Reference
Ford RL, Knight OJ, Klifto MR, et al. A Pilot Study Assessing Treatment Outcomes in Neovascular Glaucoma Using Ahmed Glaucoma Valve with and without Cyclophotocoagulation. J Curr Glaucoma Pract. 2022;16(1):4-10. doi: 10.5005/jp-journals-10078-1358. PMID: 36060048; PMCID: PMC9385394.